Table 2.
Multivariate analyses of factors affecting OS
| Variable | Adults, CR1/CR2, MAC/RIC (n = 2593) | Pediatrics, CR1/CR2, MAC (n = 1619) | Advanced disease, MAC (n = 1003) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | HR (95% CI) | P | n | HR (95% CI) | P | n | HR (95% CI) | P | ||
| Age, y | ||||||||||
| 1-9 | 941 | 1 | 187 | 1 | ||||||
| 10-18 | 678 | 1.43 (1.22-1.68) | <.0001 | 225 | 0.97 (0.75-1.25) | .80 | ||||
| 19-29 | 928 | 1 | 281 | 1.39 (1.07-1.79) | .012 | |||||
| 30-39 | 568 | 1.03 (0.89-1.20) | .68 | 139 | 1.26 (0.93-1.70) | .13 | ||||
| 40-49 | 558 | 1.28 (1.10-1.49) | .0015 | 107 | 2.10 (1.53-2.89) | <.0001 | ||||
| 50-59 | 402 | 1.66 (1.40-1.97) | <.0001 | 67 | 1.58 (1.10-2.29) | .015 | ||||
| ≥60 | 137 | 1.61 (1.20-2.15) | .0013 | 7 | 3.68 (1.40-9.68) | .0084 | ||||
| KPS score | ||||||||||
| <90% | 733 | 1 | 293 | 1 | ||||||
| 90%-100% | 1774 | 0.78 (0.69-0.88) | <.0001 | 648 | 0.81 (0.68-0.95) | .011 | ||||
| Missing | 86 | 0.90 (0.66-1.21) | .47 | 62 | 0.78 (0.56-1.09) | .15 | ||||
| Cytogenetics | ||||||||||
| Normal/standard | 1196 | 1 | 513 | 1 | ||||||
| Poor, Philadelphia positive | 957 | 0.83 (0.73-0.94) | .0029 | 150 | 0.77 (0.60-0.97) | .028 | ||||
| Poor, Philadelphia negative | 230 | 1.09 (0.89-1.32) | .41 | 95 | 1.41 (1.09-1.84) | .010 | ||||
| Missing | 210 | 1.18 (0.97-1.44) | .092 | 245 | 0.91 (0.75-1.09) | .30 | ||||
| Conditioning | ||||||||||
| MAC with TBI | 1917 | 1 | ||||||||
| MAC without TBI | 317 | 1.29 (1.09-1.53) | .0026 | |||||||
| RIC | 359 | 1.06 (0.88-1.27) | .57 | |||||||
| Donor source | ||||||||||
| Matched sibling | 903 | 1 | 197 | 1 | ||||||
| Matched URD | 934 | 1.08 (0.95-1.24) | .25 | 334 | 1.40 (1.11-1.76) | .0044 | ||||
| Mismatched URD | 433 | 1.39 (1.18-1.64) | <.0001 | 231 | 1.84 (1.44-2.35) | <.0001 | ||||
| UCB | 323 | 1.23 (0.98-1.53) | .077 | 241 | 1.37 (1.00-1.87) | .049 | ||||
| D/R CMV serology | ||||||||||
| +/+ | 763 | 1 | 249 | 1 | 227 | 1 | ||||
| +/− | 255 | 0.91 (0.75-1.11) | .36 | 115 | 1.08 (0.75-1.54) | .69 | 80 | 0.66 (0.48-0.89) | .0074 | |
| −/+ | 781 | 0.86 (0.74-1.00) | .050 | 538 | 1.35 (1.06-1.72) | .017 | 346 | 0.82 (0.66-1.02) | .069 | |
| −/− | 767 | 0.83 (0.71-0.97) | .018 | 665 | 0.94 (0.73-1.20) | .60 | 302 | 0.59 (0.47-0.74) | <.0001 | |
| Missing | 118 | 1.19 (0.92-1.53) | .18 | 52 | 0.94 (0.58-1.51) | .79 | 48 | 1.06 (0.73-1.53) | .77 | |
| GVHD prophylaxis | ||||||||||
| CNI + MTX | 1684 | 1 | 621 | 1 | ||||||
| CNI + MMF | 549 | 1.23 (1.06-1.45) | .0087 | 207 | 1.30 (1.03-1.64) | .026 | ||||
| Other | 357 | 1.10 (0.93-1.30) | .24 | 172 | 0.97 (0.77-1.23) | .82 | ||||
| Year of transplantation | ||||||||||
| 2000-2003 | 597 | 1 | 494 | 1 | 376 | 1 | ||||
| 2004-2007 | 897 | 0.90 (0.79-1.04) | .16 | 580 | 0.74 (0.61-0.89) | .0013 | 372 | 0.78 (0.65-0.93) | .0059 | |
| 2008-2011 | 619 | 0.80 (0.68-0.95) | .0086 | 337 | 0.66 (0.53-0.83) | .00040 | 175 | 0.62 (0.49-0.80) | .00020 | |
| 2012-2014 | 480 | 0.64 (0.52-0.78) | <.0001 | 208 | 0.66 (0.50-0.88) | .0050 | 80 | 0.54 (0.38-0.78) | ||
GVHD is shown separately in Figure 2.
D/R, donor/recipient; MMF, mycophenolate mofetil; MTX, methotrexate; PIF, primary induction failure.